Produced by Araxis Merge on 3/8/2018 10:14:53 AM Eastern Standard Time. See www.araxis.com for information about Merge. This report uses XHTML and CSS2, and is best viewed with a modern standards-compliant browser. For optimum results when printing this report, use landscape orientation and enable printing of background images and colours in your browser.
# | Location | File | Last Modified |
---|---|---|---|
1 | PRE_PPS-N_v3.0.1.zip\PS_PPS_srv\etc\csv\test | ProductCSV_LargeExportTest.csv | Fri Jan 12 15:43:26 2018 UTC |
2 | PRE_PPS-N_v3.0.1.zip\PS_PPS_srv\etc\csv\test | ProductCSV_LargeExportTest.csv | Wed Mar 7 18:46:14 2018 UTC |
Description | Between Files 1 and 2 |
|
---|---|---|
Text Blocks | Lines | |
Unchanged | 3 | 6 |
Changed | 4 | 40 |
Inserted | 0 | 0 |
Removed | 0 | 0 |
Whitespace | |
---|---|
Character case | Differences in character case are significant |
Line endings | Differences in line endings (CR and LF characters) are ignored |
CR/LF characters | Not shown in the comparison detail |
No regular expressions were active.
1 | DNS ductName^O iName^Prop Inactivati onDate^Syn onymMultip le^Witness Required^P atientSpec ificLabel^ ProtectFro mLight^DoN otHandlePr egnant^Fol lowUpTime^ HazardToDi spose^Haza rdToHandle ^HazardToP atient^Lon gTermOutOf Stock^LowS afetyMargi n^NonRenew able^LabMo nitorMarkF ormulary^N cpdpDispen seUnit^Ncp dpQtyMulti plier^Appr ovedForSpl itting^DoN otMail^ArW sAmisCateg ory^ArWsAm isConvertN umber^DawC ode^DayOrD oseLimit^D ispDaysSup plyLimit^D ispLimitFo rOrder^Dis pLimitForS chedule^Di spOverride ^DispOverr ideReason^ DispQtyLim itDose^Dis pQtyLimitT ime^DispQt yOverride^ DispQtyOve rrideReaso n^DispUnit PerOrderUn it^FsnNsn^ HighRiskMe d^HighRisk Followup^H ighRiskFol lowupTime^ InpatMedEx pOrdMaxTim e^InpatMed ExpOrdMinT ime^MaxDis penseLimit ^MaxDosePe rDay^RxMes sage^Monit orMaxDays^ OrderUnit^ DispOverri deReasonBy ^QtyDispMe ssage^Requ estRejectR eason^Reje ctReasonTe xt^Seconda ryVaDrugCl ass^TotalD ispenseQty ^UnitDoseS chedule^Un itDoseSche duleType^R efrigerati on^Default MailServic e^RecallLe vel^Tallma nLettering ^DeaSchedu le^Monitor Routine^Na tDrugText^ NumberOfDo ses ,, | |
2 | ACETAMINOP HEN 325MG TAB^ACETAM INOPHEN-N TAB^^^N^N^ N^N^N^N^N^ N^N^N^N^N^ FORMULARY^ EA-EACH^1^ ^N^^^0-NO PRODUCT SE LECTION IN DICATED^^^ ^^^^0^0^^^ ^^N^N^^^^^ 1^^^^^^^^^ ^^^^^^^0-U nscheduled ^^DT5^ ,, | |
3 | DIGOXIN 0. 25MG TAB^D IGOXIN TAB ^^^N^N^N^N ^N^N^N^N^N ^N^N^N^FOR MULARY^EA- EACH^1^^N^ ^^0-NO PRO DUCT SELEC TION INDIC ATED^^^^^^ ^0^0^^^^^N ^N^^^^^1^^ ^^^^^^^^^^ ^^^^0-Unsc heduled^^D T5^ ,, | |
4 | LISINOPRIL 10MG TAB^ LISINOPRIL TAB^^^N^N ^N^N^N^N^N ^N^N^N^N^N ^FORMULARY ^EA-EACH^1 ^^N^^^0-NO PRODUCT S ELECTION I NDICATED^^ ^^^^^0^0^^ ^^^N^N^^^^ ^1^^^^^^^^ ^^^^^^^^0- Unschedule d^^DT5^ ,, | |
5 | LISINOPRIL 40MG TAB^ LISINO-N T AB^^^N^N^N ^N^N^N^N^N ^N^N^N^N^F ORMULARY^E A-EACH^1^^ N^^^0-NO P RODUCT SEL ECTION IND ICATED^^^^ ^^^0^0^^^^ ^N^N^^^^^1 ^^^^^^^^^^ ^^^^^^0-Un scheduled^ ^DT5^ ,, | |
6 | PSEUDOEPHE DRINE HCL 60MG TAB^P SEUDOEPHED RINE-N HCL TAB^^^N^N ^N^N^N^N^N ^N^N^N^N^N ^FORMULARY ^EA-EACH^1 ^^N^^^0-NO PRODUCT S ELECTION I NDICATED^^ ^^^^^0^0^^ ^^^N^N^^^^ ^1^^^^^^^^ ^^^^^^^^0- Unschedule d^^DT5^ ,, | |
7 | SIMVASTATI N 40MG TAB ^SIMVASTAT IN TAB^^^N ^N^N^N^N^N ^N^N^N^N^N ^N^FORMULA RY^EA-EACH ^1^^N^^^0- NO PRODUCT SELECTION INDICATED ^^^^^^^0^0 ^^^^^N^N^^ ^^^1^^^^^^ ^^^^^^^^^^ 0-Unschedu led^^DT5^ ,, | |
8 | ATOMOXETIN E 60MG CAP ^ATOMOXETI NE CAP^^^N ^N^N^N^N^N ^N^N^N^N^N ^N^FORMULA RY^EA-EACH ^1^^N^^^0- NO PRODUCT SELECTION INDICATED ^^^^^^^0^0 ^^^^^N^N^^ ^^^1^^^^^^ ^^^^^^^^^^ 0-Unschedu led^^DT5^ ,, | |
9 | TEMAZEPAM 15MG CAP,O RAL^TEMAZE PAM CAP^^^ N^N^N^N^N^ N^N^N^N^N^ N^N^FORMUL ARY^EA-EAC H^1^^N^^^0 -NO PRODUC T SELECTIO N INDICATE D^^^^^^^0^ 0^^^^^N^N^ ^^^^1^^^^^ ^^^^^^^^^^ ^0-Unsched uled^^DT5^ , | |
10 | OXYMORPHON E HCL 10MG TAB^OXYMO RPHONE HCL TAB^^^N^N ^N^N^N^N^N ^N^N^N^N^N ^FORMULARY ^EA-EACH^1 ^^N^^^0-NO PRODUCT S ELECTION I NDICATED^^ ^^^^^0^0^^ ^^^N^N^^^^ ^1^^^^^^^^ ^^^^^^^^0- Unschedule d^^DT5^ ,, | |
11 | RISPERIDON E 2MG TAB, ORAL DISIN TEGRATING^ RISPERIDON E TAB,ORAL DISINTEGR ATING^^^N^ N^N^N^N^N^ N^N^N^N^N^ N^FORMULAR Y^EA-EACH^ 1^^N^^^0-N O PRODUCT SELECTION INDICATED^ ^^^^^^0^0^ ^^^^N^N^^^ ^^1^^^^^^^ ^^^^^^^^^0 -Unschedul ed^^DT5^ | |
12 | ACARBOSE 1 00MG TAB^A CARBOSE TA B^^PRECOSE ::00026-28 62-51::::: :0-TRADE N AME::BT::4 8.63::100. 0::0.49^N^ N^N^N^N^N^ N^N^N^N^N^ N^FORMULAR Y^EA-EACH^ 1^^N^^^0-N O PRODUCT SELECTION INDICATED^ ^^^^^^0^0^ ^^^^N^N^^^ ^^0^^^^^^^ ^^^^^^^^^0 -Unschedul ed^^^ ,, | |
13 | AMOXICILLI N TRIHYDRA TE 500MG/C LAVULANATE K 125MG T AB^AMOXICI LLIN/CLAVU LANATE TAB ^^^N^N^N^N ^N^N^N^N^N ^N^N^N^FOR MULARY^EA- EACH^1^^N^ ^^0-NO PRO DUCT SELEC TION INDIC ATED^^^^^^ ^0^0^^^^^N ^N^^^^^0^^ ^^^^^^^^^^ ^^^^0-Unsc heduled^^^ ,, | |
14 | ATROPINE S O4 1% OINT ,OPH^ATROP INE OINT,O PH^^000000 2185117::0 000002-185 1-17:::::: D-DRUG ACC OUNTABILIT Y::TU::0.9 4::1.0::0. 94||ISOPTO ATROPINE: :0000002-1 851-17:::: ::0-TRADE NAME::TU:: 0.94::1.0: :0.94^N^N^ N^N^N^N^N^ N^N^N^N^N^ FORMULARY^ EA-EACH^1^ ^N^^^0-NO PRODUCT SE LECTION IN DICATED^^^ ^^^^0^0^^^ ^^N^N^^^^^ 0^^^^^^^^^ ^^^^^^^0-U nscheduled ^^^ | |
15 | CELECOXIB 200MG CAP^ CELECOXIB CAP,ORAL^^ ^N^N^N^N^N ^N^N^N^N^N ^N^N^FORMU LARY^EA-EA CH^1^^N^^^ 0-NO PRODU CT SELECTI ON INDICAT ED^^^^^^^0 ^0^^^^^N^N ^^^^^0^^^^ ^^^^^^^^^^ ^^0-Unsche duled^^^ , | |
16 | CEPHALEXIN 250MG/5ML SUSP^CEPH ALEXIN PWD R,RENST-OR AL^^^N^N^N ^N^N^N^N^N ^N^N^N^N^F ORMULARY^E A-EACH^1^^ N^^^0-NO P RODUCT SEL ECTION IND ICATED^^^^ ^^^0^0^^^^ ^N^N^^^^^0 ^^^^^^^^^^ ^^^^^^0-Un scheduled^ ^^ , | |
17 | CLONIDINE 0.3MG/24HR S PATCH^CL ONIDINE PA TCH^^^N^N^ N^N^N^N^N^ N^N^N^N^N^ FORMULARY^ EA-EACH^1^ ^N^^^0-NO PRODUCT SE LECTION IN DICATED^^^ ^^^^0^0^^^ ^^N^N^^^^^ 0^^^^^^^^^ ^^^^^^^0-U nscheduled ^^^ ,, | |
18 | IBUPROFEN 400MG TAB^ IBUPROFEN TAB^^IBUPR OFEN 400MG TAB::5374 6-0131-05: :::::0-TRA DE NAME::B T::5.6::50 0.0::0.01^ N^N^N^N^N^ N^N^N^N^N^ N^N^FORMUL ARY^EA-EAC H^1^^N^^^0 -NO PRODUC T SELECTIO N INDICATE D^^^^^^^0^ 0^^^^^N^N^ ^^^^0^^^^^ ^^^^^^^^^^ ^0-Unsched uled^^^ ,, | |
19 | LITHIUM CA RBONATE 30 0MG TAB,SA ^LITHIUM T AB,SA^^^N^ N^N^N^N^N^ N^N^N^N^N^ N^FORMULAR Y^EA-EACH^ 1^^N^^^0-N O PRODUCT SELECTION INDICATED^ ^^^^^^0^0^ ^^^^N^N^^^ ^^0^^^^^^^ ^^^^^^^^^0 -Unschedul ed^^^ | |
20 | LINDANE 1% SHAMPOO^L INDANE SHA MPOO^^0172 36077116:: 017236-077 1-16:::::: D-DRUG ACC OUNTABILIT Y::BT::59. 26::60.0:: 0.99||BENZ ENE HEXACH LORIDE SHA MPOO::0021 -0610-16:: ::::0-TRAD E NAME::BT ::59.26::6 0.0::0.99| |KWELL SHA MPOO::0021 -0610-16:: ::::0-TRAD E NAME::BT ::59.26::6 0.0::0.99| |GAMMA BEN ZENE::0021 -0610-16:: ::::0-TRAD E NAME::BT ::59.26::6 0.0::0.99| |KWELL::00 21-0610-16 ::::::0-TR ADE NAME:: BT::59.26: :60.0::0.9 9^N^N^N^N^ N^N^N^N^N^ N^N^N^FORM ULARY^EA-E ACH^1^^N^^ ^0-NO PROD UCT SELECT ION INDICA TED^^^^^^^ 0^0^^^^^N^ N^^^^^0^^^ ^^^^^^^^^^ ^^^0-Unsch eduled^^^ ,, | |
21 | LORAZEPAM 1MG TAB^LO RAZEPAM TA B^^ATIVAN 1MG::0008- 0064-02::: :::0-TRADE NAME::BT: :9.45::100 .0::0.1||0 0000800640 2::0008-00 64-02::::: :D-DRUG AC COUNTABILI TY::BT::9. 45::100.0: :0.1||ATIV AN::0008-0 064-02:::: ::0-TRADE NAME::BT:: 9.45::100. 0::0.1^N^N ^N^N^N^N^N ^N^N^N^N^N ^FORMULARY ^EA-EACH^1 ^^N^^^0-NO PRODUCT S ELECTION I NDICATED^^ ^^^^^0^0^^ ^^^N^N^^^^ ^0^^^^^^^^ ^^^^^^^^0- Unschedule d^^^ ,, | |
22 | WARFARIN N A 7.5MG TA B^WARFARIN TAB^^WARF ARIN (COUM ADIN) NA 7 .5MG TAB:: 00056-0173 -70::::::1 -QUICK COD E::BT::19. 27::100.0: :0.19||COU MADIN::000 56-0173-70 ::::::1-QU ICK CODE:: BT::19.27: :100.0::0. 19^N^N^N^N ^N^N^N^N^N ^N^N^N^FOR MULARY^EA- EACH^1^^N^ ^^0-NO PRO DUCT SELEC TION INDIC ATED^^^^^^ ^0^0^^^^^N ^N^^^^^0^^ ^^^^^^^^^^ ^^^^0-Unsc heduled^^^ ,, | |
23 | ACETAMINOP HEN 523MG TAB^OPIUM TAB^201109 12^Name2:: 12345-9999 -45::Vendo r2::VSN2:: 1-QUICK CO DE::PT::17 .01::17.02 ::17.03||N ame1::1234 5-9999-44: :Vendor1:: VSN1::D-DR UG ACCOUNT ABILITY::B X::11.11:: 22.22::33. 33^Y^Y^Y^Y ^Y^Y^Y^Y^Y ^Y^Y^Y^FOR MULARY WIT H RESTRICT IONS^ML-MI LLILITERS^ 12^Y^Y^3-B LOOD PRODU CT^6000^7- SUBSTITUTI ON NOT ALL OWED-BRAND DRUG MAND ATED BY LA W^45D^255^ There is a high limi t for this order^The re is a lo w limit fo r this sch edule^You should ove rride this ^This is t he overrid e^800^85^Q uantity Ov erride is entered^Th e reason f or the ove rride^222. 3344^FSN10 0/NSN200^Y ^Y^EVERY 1 6 Minutes^ 400 Days^2 0 Minutes^ 372.90879^ 25^This is the Rx--M essage^899 ^BX^Todd S chippers^D ispense Th is Quantit y^INAPPROP RIATE_REQU EST^Reject this item ^LINCOMYCI NS::AM350| |INVESTIGA TIONAL GEN E THERAPY: :IN950^Tot al Dispens y Quantity ^3 Hours^P - PRN^Y^F ederal Exp ress^2-CLA SS 2^tallm anLETTERin g^6-Legend Item^RN37 B^DT1||DT4 ^172 ,, |
Araxis Merge (but not the data content of this report) is Copyright © 1993-2016 Araxis Ltd (www.araxis.com). All rights reserved.